drugset / Trial / NCT06254326
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
Timeline
- Start
- 2024-09-19
- Primary completion
- 2027-12
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TTRNA-DC | Cell therapy | — | Other |
| Subject | TTRNA-xALT | Cell therapy | — | Intravenous |
| Background | Autologous Hematopoietic Stem cells (HSCs) | Cell therapy | — | Intravenous |
| Background | Td vaccine | Vaccine | — | Intramuscular |
| Background | sargramostim | Protein / enzyme biologic | — | — |